Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

Pharmacogenetics and Genomics

Volumn 17, Issue 10, 2007, Pages 841-844

  Mercier, Cédric ^a,b   Raynal, Caroline ^c   Dahan, Laetitia ^b   Ortiz, Adrien ^a   Evrard, Alexandre ^c   Dupuis, Charlotte ^a,b   Blesius, Aurore ^b   Duluc, Muriel ^b   Franceschini, Fleur ^a   Giacometti, Sarah ^a   Salas, Sébastien ^b   Milano, Gérard ^d   Favre, Roger ^a,b   Seitz, Jean François ^b   Ciccolini, Joseph ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cytidine deaminase; Gemcitabine; Gene polymorphism; Phenotype genotype; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CYTIDINE DEAMINASE; GEMCITABINE; GROWTH FACTOR;

AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DOWN REGULATION; DRUG FATALITY; ENZYME DEFICIENCY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; MALE; METASTASIS; MUTATION; NEUTROPENIA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RISK; SEPSIS; THROMBOCYTOPENIA;

AGED; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DOWN-REGULATION; FATAL OUTCOME; FEMALE; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES;

EID: 34648847288     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32825ea6e3     Document Type: Article

References (15)

1. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12:1794-1803.
2. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006; 119:276-283.
3. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25:32-42.
4. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26:421-425.
5. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998; 103:1096-1103.
6. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13:29-38.
7. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11:2620-2624.
8. Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, et al. Dose individualization of carboplatin after a 120-h infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 2006; 28:212-218.
9. Okamura T, Kigasawa K, Takeuchi T, Ohta C. Cytidine deaminase activity in abnormal pregnancy. Int J Gynaecol Obstet 1993; 41:53-60.
10. Herrmann MG, Durtschi JD, Bromley LK, Wittwer CT, Voelkerding KV. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 2006; 52:494-503.
11. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-137.
12. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006; 6:288-296.
13. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14:567-572.
14. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. GT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226-1236.
15. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468.